SB1774 amends title 5 by adding subsection (q) to 5 U.S.C. 8902 and prevents contracts under the Federal Employees Health Benefits (FEHB) program from covering gender‑affirming care or services for anyone under age 18. The bill defines “gender‑affirming care or service” to include hormone therapy, puberty blockers, and surgical procedures for gender transition, while listing explicit medical exceptions (disorders of sexual development, certain genetic or biochemical diagnoses, treatment of complications, emergency life‑saving procedures, and other narrowly described puberty‑related treatments and male circumcision).
The statute would also permit a limited continuity period for minors already receiving covered hormone therapy on the bill’s effective date: coverage may continue only under a physician‑supervised reduction schedule that must end within one year. The prohibition applies to FEHB contracts entered into or renewed for a contract year on or after enactment, forcing plan sponsors, carriers, OPM, providers, and affected families to alter benefits design, claims adjudication, and clinical workflows.
At a Glance
What It Does
The bill inserts subsection (q) into 5 U.S.C. 8902 to define “gender‑affirming care or service” and to bar FEHB contracts from covering those services for individuals under 18, subject to enumerated medical exceptions and a narrow grandfathering rule for existing hormone therapy. It requires physician supervision for any permitted wind‑down and limits continuation to one year after the statute’s effective date.
Who It Affects
Directly affects the Office of Personnel Management (OPM) as FEHB program administrator, FEHB plan sponsors and carriers, federal employees and their dependents under age 18, and clinicians who deliver pediatric endocrinology or gender‑related services to federal beneficiaries. It also implicates claims processors and benefit managers who will implement coverage changes.
Why It Matters
SB1774 sets a federal baseline for what FEHB— the largest employer‑sponsored federal plan—must exclude, prompting immediate plan redesign, potential denials of care for minors covered by FEHB, and likely operational and legal challenges over medical definitions, exception criteria, and enforcement procedures.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill targets the Federal Employees Health Benefits program by amending the statute that defines what federal plans may cover. Rather than leaving coverage decisions solely to carriers or OPM policy guidance, SB1774 adds a textually explicit prohibition: FEHB contracts may not cover gender‑affirming treatments for beneficiaries under age 18.
The statute contains a working definition that lists hormone therapy, puberty blockers, and surgical procedures as covered by the prohibition, while carving out several medically specific exceptions.
Those exceptions are narrowly framed. The bill exempts treatment for people born with disorders of sexual development (DSDs) and disorders proven by genetic or biochemical testing that affect sex chromosome structure or sex steroid hormone production/action.
It also exempts procedures performed to address infections, injuries, diseases, or disorders caused or worsened by prior gender‑affirming interventions, and emergency procedures needed to prevent death or major bodily impairment. Additionally, the statute clarifies that standard pediatric treatments for precocious or delayed puberty consistent with the child’s biological sex, and male circumcision, are not swept up by the prohibition.SB1774 builds a short, specific grandfathering path: minors who, on the effective date, are already receiving hormone therapy covered by FEHB may continue that therapy only if it is placed on a physician‑supervised reduction schedule that must conclude no later than one year after the effective date.
That creates an operational requirement for clinicians to document and supervise tapering and for plans to accept or audit such schedules. For new initiations of the listed interventions, the prohibition is categorical for under‑18s.Finally, the bill’s applicability is transactional: it applies to FEHB contracts entered into or renewed for a contract year on or after enactment.
That timing means carriers and OPM will implement coverage design and claims changes as contracts turn over, giving some predictability but also requiring immediate rule‑writing, coding updates, and provider notifications to avoid retroactive payment disputes.
The Five Things You Need to Know
SB1774 adds a new subsection (q) to 5 U.S.C. 8902 that defines and governs coverage of “gender‑affirming care or service.”, The bill expressly defines gender‑affirming care to include hormone therapy, puberty blockers, and any surgical procedure aimed at gender transition.
The statute lists explicit medical exceptions—disorders of sexual development, genetically/biochemically diagnosed sex‑related disorders, treatment of complications from prior interventions, emergency procedures for imminent risk, certain puberty treatments consistent with biological sex, and male circumcision.
For beneficiaries already on covered hormone therapy on the bill’s effective date, coverage may continue only under a physician‑supervised reduction schedule that must end within one year of that date.
The prohibition applies to any FEHB contract entered into, or renewed for a contract year, on or after enactment, making implementation tied to contract cycles.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the bill’s short name: the “Protecting Minors in Federal Health Plans Act.” This is a formal label but also signals the statute’s focus on benefit design for minors covered under federal employee health plans and frames subsequent provisions as federal programmatic change rather than ad‑hoc guidance.
Definition of 'gender‑affirming care or service' and enumerated exclusions
Adds a multi‑clause definition that treats medical interventions designed to treat gender dysphoria as ‘gender‑affirming care,’ explicitly listing hormone therapy, puberty blockers, and surgical procedures. It then carves out several specific exclusions—DSDs, certain genetically or biochemically demonstrable disorders affecting sex characteristics, treatment of complications from prior interventions, emergency procedures for imminent life or major‑function risk, medically indicated puberty treatments consistent with biological sex, and male circumcision. Practically, the list forces claims adjudicators and clinicians to assess eligibility against diagnostic and testing standards, and it raises questions about what documentation carriers will require to authenticate an exclusion.
Flat prohibition on coverage for under‑18 beneficiaries
Imposes a categorical ban on including coverage for any defined gender‑affirming care or service for individuals under 18 in FEHB contracts, subject only to the listed exceptions. For plan administrators this is a bright‑line coverage rule: new authorizations, prior authorizations, and claims for the covered services for under‑18s should be denied absent a qualifying exclusion. That creates an operational demand for updated medical necessity criteria, prior‑authorization rules, and coding edits to prevent improper payments.
Narrow grandfathering for ongoing hormone therapy
Grants a narrow, time‑limited continuity option for minors already receiving FEHB‑covered hormone therapy when the statute takes effect: coverage may continue only if the therapy is placed on a physician‑supervised reduction schedule and must end no later than one year after the effective date. This clause creates an affirmative evidence requirement (a supervised taper) that clinicians must produce and that plans may audit. It also forces difficult clinical and coordination choices for families and providers who must plan transition off therapy within a year.
Contract‑year implementation trigger
States that the amendment applies to any FEHB contract entered into, or renewed for a contract year, on or after the date of enactment. Implementation therefore follows commercial contracting cycles: some beneficiaries will see immediate changes when their plan year begins, while others may retain existing coverage until contract renewal. OPM and carriers will need to issue benefit amendments, update enrollment materials, and align plan documents and billing systems to the new statutory baseline.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- FEHB plan sponsors and some carriers — narrows covered services for a large beneficiary population, which can reduce utilization exposure and simplify benefit design for pediatric gender‑related services.
- Federal employers (agencies) — may see downward pressure on employer share of FEHB premiums if utilization declines, and they obtain a clearer statutory boundary for covered pediatric services.
- Policy advocates and families opposed to pediatric gender‑affirming interventions — gain a federal statutory mechanism that restricts coverage for minors across the FEHB program.
- Administrators of the FEHB program (OPM) — obtain a statutory rule rather than discretionary guidance, which can simplify program management and justify uniform plan terms.
Who Bears the Cost
- Minors with gender dysphoria covered under FEHB — face loss of covered access to puberty blockers, hormones, and transition surgeries, except in narrowly defined circumstances, disrupting ongoing care and forcing out‑of‑pocket payment or loss of treatment.
- Federal employees and families — could incur higher out‑of‑pocket costs or need to change plans or providers to obtain care, and may experience administrative disputes over eligibility for exceptions or grandfathering.
- FEHB carriers and third‑party administrators — must change plan designs, update coding and prior‑authorization rules, train staff, and potentially process more appeals and audits; administrative transition carries direct compliance costs.
- Clinicians and specialty providers (pediatric endocrinologists, surgeons, mental‑health professionals) — will lose reimbursement for many services to FEHB‑covered minors and face greater documentation and audit risk for exceptions and grandfathered cases.
- OPM and federal agencies — incur rulemaking, oversight, and enforcement costs as they update contracts, create interpretive guidance, and respond to beneficiary and provider disputes.
Key Issues
The Core Tension
The bill pits a policy goal—preventing minors from receiving certain gender‑transition interventions via federal coverage—against established medical judgment and clinical standards for treating gender dysphoria and related conditions. That trade‑off forces a choice between uniform statutory limits aimed at protecting minors and preserving clinician discretion to diagnose and treat on a case‑by‑case basis; resolving it will require rules that necessarily favor enforceability over clinical nuance, or vice versa.
The bill attempts a tidy statutory fix—an explicit prohibition with enumerated exceptions and a short grandfathering window—but it leaves several implementation details unresolved. The statute depends heavily on diagnostic and laboratory‑based exclusions (DSDs and biochemical/genetic testing), yet it does not prescribe evidentiary standards, who performs or certifies the testing, or the documentation carriers may request.
That will force carriers and OPM to develop operational rules that could vary in stringency and produce inconsistent access across plans.
The physician‑supervised reduction schedule requirement for existing hormone therapy is another practical gray area. The statute mandates supervision and a one‑year endpoint but does not define what constitutes an acceptable taper plan, how plans should audit compliance, or how to treat clinical exceptions where stopping therapy may cause medical harm.
Those gaps set the stage for provider disputes, appeals, and litigation. Finally, the bill’s narrow exception language (e.g., “imminent risk of death or impairment of major bodily function”) creates coverage tension in emergency and urgent care settings where decisions are time‑sensitive and documentation may arrive after the fact, increasing the risk of retroactive claim denials or payment disputes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.